Sokolove Jeremy, Lindstrom Tamsin M, Robinson William H
Geriatric Research Education and Clinical Center, VA Palo Alto Health Care System, Palo Alto, CA 94304, USA.
Front Biosci (Elite Ed). 2012 Jan 1;4(1):320-30. doi: 10.2741/379.
Recent developments in proteomic technologies have enabled the high-throughput, multiplex measurement of large panels of antibodies in biological fluids of patients with immune-driven diseases. Antigen microarrays are increasingly being used to delineate the natural history of autoantibody formation and epitope spread, and thus gain insight into the pathogenesis of autoimmune diseases, as well as into host immunity and its shortcomings. Characterization of autoimmunity that precedes the onset of clinically apparent disease has the potential to guide disease prevention using either conventional immunosupression or novel, antigen-specific tolerizing therapies. In addition, autoantibody profiling has the potential to identify molecular subtypes of a disease, which could allow for prediction of disease outcomes such as severity, tissue damage, and response to therapy.
蛋白质组学技术的最新进展使得在免疫驱动疾病患者的生物体液中能够对大量抗体进行高通量、多重测量。抗原微阵列越来越多地被用于描绘自身抗体形成的自然史和表位扩散，从而深入了解自身免疫性疾病的发病机制，以及宿主免疫及其缺陷。对临床明显疾病发作之前的自身免疫进行特征化，有可能通过传统的免疫抑制或新型的、抗原特异性耐受疗法来指导疾病预防。此外，自身抗体谱分析有可能识别疾病的分子亚型，这可以预测疾病的结果，如严重程度、组织损伤和对治疗的反应。
